logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
S

Swantje Held

clinassess gmbh
H指数:24
被引数:2,772

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Quality of life in patients with RAS wild-type metastatic colorectal cancer treated mFOLFOXIRI + panitumumab versus FOLFOXIRI: a prespecified secondary analysis of the phase II VOLFI AIO-KRK 0109 trial

携带RAS野生型转移性结直肠癌患者接受mFOLFOXIRI +帕尼单抗与FOLFOXIRI治疗的生活质量：VOLFI AIO-KRK 0109 II期试验的预设次要分析

European Journal of Cancer
IF7.1
2026-09-110
OA
Tshilidzi M. Klingler; Uwe M. Martens; Jorge Riera-Knorrenschild; Swen Wessendorf; Thomas Ettrich; Stephan Kanzler; Sophie Lugani; Elena Rohleder; Arndt Stahler; Alena A. Hasenburg; Swantje Held; Petra Buechner-Steudel; Jens Atzpodien; Volker Heinemann; Michael Geissler; Dominik P. Modest; Johannes Werner
Impact of Sex on Efficacy and Safety of 1st-Line Treatment with FOLFIRI plus Cetuximab or Bevacizumab in RAS/BRAF Wildtype Metastatic Colorectal Cancer– A subgroup analysis of the FIRE-3 (AIO KRK-0306) Trial

性別对FOLFIRI联合西妥昔单抗或贝伐珠单抗作为RAS/BRAF野生型转移性结直肠癌一线治疗方案有效性和安全性的影响——FIRE-3 (AIO KRK-0306)试验的亚组分析

European Journal of Cancer
IF7.1
2025-11-220
PRE
Kathrin Heinrich; Sebastian Stintzing; Ludwig Fischer von Weikersthal; Thomas Decker; Alexander Kiani; Florian Kaiser; Salah-Eddin Al-Batran; Tobias Heintges; Christoph Lerchenmüller; Christoph Kahl; Gernot Seipelt; Frank Kullmann; Markus Moehler; Werner Scheithauer; Andreas Jung; Julian W. Holch; Swantje Held; Dominik Paul Modest; Volker Heinemann
Sorafenib as first-line therapy for metastatic uveal melanoma: A multicenter, placebo-controlled randomized discontinuation study (STREAM)

索拉非尼作为转移性葡萄膜黑色素瘤的一线疗法：一项多中心、安慰剂对照的随机中止研究（STREAM）

iScience
IF4.1
2025-11-140
OAAI
Halime Kalkavan; Max E. Scheulen; Eckhart Kämpgen; Ulrich Keilholz; Lucie Heinzerling; Smiths S. Lueong; Annalena Hlinka; Tanja Gromke; Sebastian Ochsenreither; Ralf-Axel Hilger; Matthias Grubert; Axel Wetter; Nika Guberina; Michael Zeschnigk; Peter Ferency; Swantje Held; Axel Hinke; Gerold Schuler; Karim Al-Ghazzawi; Norbert Bornfeld
First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAFV600E-mutated metastatic colorectal cancer according to primary tumor sidedness: a pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group)

抗EGFR抗体与抗VEGF抗体在BRAFV600E突变型转移性结直肠癌中根据原发肿瘤侧性的初始治疗疗效：一项在mCRC初始治疗中进行的七项临床试验的合并分析（德国AIO研究组）

European Journal of Cancer
IF7.1
2025-11-130
OAAI
Lena Weiss; Sebastian Stintzing; Dominik Paul Modest; Arndt Stahler; Ludwig Fischer von Weikersthal; Anke Reinacher-Schick; Thomas Decker; Victoria Probst; Kathrin Heinrich; Ingo Schwaner; Florian Kaiser; Rudolf Pihusch; Martin Fuchs; Swantje Held; Annabel Alig; Birgit Gruenberger; Gerald Werner Prager; David Tougeron; Julien Taieb; Volker Heinemann
Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAF V600E mutated colorectal cancer-results from the FIRE-4.5 study
MOLECULAR ONCOLOGY
IF4.5
2024-12-040
PRE
Klein-Scory, Susanne; Baraniskin, Alexander; Schmiegel, Wolff; Mika, Thomas; Schroers, Roland; Held, Swantje; Heinrich, Kathrin; Tougeron, David; Modest, Dominik P.; Schwaner, Ingo; Eucker, Jan; Pihusch, Rudolf; Stauch, Martina; Kaiser, Florian; Kahl, Christoph; Karthaus, Meinolf; Mueller, Christian; Burkart, Christof; Stintzing, Sebastian; Heinemann, Volker
Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113) (vol 7, 100552, 2024)
ESMO OPEN
IF8.3
2024-10-010
OAAI
Hartlapp, I.; Valta-Seufzer, D.; Siveke, J. T.; Alguel, H.; Goekkurt, E.; Siegler, G.; Martens, U. M.; Waldschmidt, D.; Pelzer, U.; Fuchs, M.; Kullmann, F.; Boeck, S.; Ettrich, T. J.; Held, S.; Keller, R.; Anger, F.; Germer, C. T.; Stang, A.; Kimmel, B.; Heinemann, V.; Kunzmann, V.
Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial
LANCET GASTROENTEROLOGY & HEPATOLOGY
IF38.6
2024-10-011
PRE
Dorman, Klara; Boeck, Stefan; Caca, Karel; Reichert, Maximilian; Ettrich, Thomas J.; Oettle, Helmut; Waidmann, Oliver; Modest, Dominik P.; Mueller, Lothar; Michl, Patrick; Kanzler, Stephan; Pink, Daniel; Reinacher-Schick, Anke; Geissler, Michael; Pelz, Henning; Kunzmann, Volker; Held, Swantje; Schichtl, Thomas; Heinemann, Volker; Kullmann, Frank
Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI
ESMO OPEN
IF8.3
2024-09-010
OAAI
Alig, A. H. S.; Modest, D. P.; Stintzing, S.; Heinrich, K.; Geissler, M.; von Weikersthal, L. Fischer; Decker, T.; Vehling-Kaiser, U.; Held, S.; Moosmann, N.; Stahler, A.; Tannapfel, A.; Giessen-Jung, C.; Jung, A.; Weiss, L.; Heinemann, V.
Dermatology-related quality-of-life outcomes in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab (Pmab) maintenance after FOLFOX D Pmab induction: a prespecified secondary analysis of the phase II randomized PanaMa (AIO KRK 0212) trial
ESMO OPEN
IF8.3
2024-07-010
OAAI
Ballhausen, A.; Karthaus, M.; Fruehauf, S.; Graeven, U.; Mueller, L.; Koenig, A. O.; von Weikersthal, L. F.; Sommerhaeuser, G.; Jelas, I.; Alig, A. H. S.; Kurreck, A.; Stahler, A.; Goekkurt, E.; Held, S.; Kasper, S.; Heinrich, K.; Heinemann, V.; Stintzing, S.; Trarbach, T.; Modest, D. P.
Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic colorectal cancer: Subgroup analysis of patients treated within the PanaMa trial (AIO KRK 0212)
INTERNATIONAL JOURNAL OF CANCER
IF4.7
2023-10-152
OA
Sommerhaeuser, Greta; Karthaus, Meinolf; Kurreck, Annika; Ballhausen, Alexej; Meyer-Knees, Johanna W.; Fruehauf, Stefan; Graeven, Ullrich; Mueller, Lothar; Koenig, Alexander O.; Weikersthal, Ludwig Fischer V.; Goekkurt, Eray; Haas, Siegfried; Stahler, Arndt; Heinemann, Volker; Held, Swantje; Alig, Annabel H. S.; Kasper-Virchow, Stefan; Stintzing, Sebastian; Trarbach, Tanja; Modest, Dominik P.
The systemic proteome of consensus molecular subtypes from patients with RAS wild-type metastatic colorectal cancer: Analysis from the randomized phase II PanaMa (AIO KRK0212) trial
ANNALS OF ONCOLOGY
IF65.4
2023-10-010
OA
Ballhausen, A.; Shomroni, O.; Stahler, A.; Hoppe, B.; Karthaus, M.; Fruehauf, S.; Graeven, U.; Sommerhaeuser, G. M.; Alig, A. H. S.; Goekkurt, E.; Meyer-Knees, J.; Kurreck, A.; Held, S.; Kasper-Virchow, S.; Heinemann, V.; Stintzing, S.; Trarbach, T.; Mulleder, M.; Ralser, M.; Modest, D. P.
Health-related quality of life in patients with RAS wild- type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial
EUROPEAN JOURNAL OF CANCER
IF7.1
2023-09-013
PRE
Ballhausen, Alexej; Karthaus, Meinolf; Fruehauf, Stefan; Graeven, Ullrich; Mueller, Lothar; Koenig, Alexander Otto; von Weikersthal, Ludwig Fischer; Sommerhaeuser, Greta; Alig, Annabel Helga Sophie; Goekkurt, Eray; Meyer-Knees, Johanna Wanda; Kurreck, Annika; Stahler, Arndt; Held, Swantje; Kasper, Stefan; Heinrich, Kathrin; Heinemann, Volker; Stintzing, Sebastian; Trarbach, Tanja; Modest, Dominik Paul
Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212)*
ESMO OPEN
IF8.3
2023-08-014
OAAI
Heinrich, K.; Karthaus, M.; Fruehauf, S.; Graeven, U.; Mueller, L.; Koenig, A. O.; von Weikersthal, L. Fischer; Caca, K.; Kretzschmar, A.; Goekkurt, E.; Haas, S.; Alig, A. H. S.; Kurreck, A.; Stahler, A.; Held, S.; Sommerhaeuser, G.; Heinemann, V.; Stintzing, S.; Trarbach, T.; Modest, D. P.
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212)
EUROPEAN JOURNAL OF CANCER
IF7.1
2023-01-012
PRE
Sommerhauser, Greta; Kurreck, Annika; Beck, Alexander; Fehrenbach, Uli; Karthaus, Meinolf; Fruehauf, Stefan; Graeven, Ullrich; Mueller, Lothar; Koenig, Alexander O.; Weikersthal, Ludwig F. v.; Goekkurt, Eray; Haas, Siegfried; Stahler, Arndt; Heinemann, Volker; Held, Swantje; Alig, Annabel H. S.; Kasper, Stefan; Stintzing, Sebastian; Trarbach, Tanja; Modest, Dominik P.
First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110)
EUROPEAN JOURNAL OF CANCER
IF7.1
2022-09-012
PRE
Stahler, Arndt; Modest, Dominik P.; von Weikersthal, Ludwig Fischer; Kaiser, Florian; Decker, Thomas; Held, Swantje; Graeven, Ullrich; Schwaner, Ingo; Denzlinger, Claudio; Schenk, Michael; Kurreck, Annika; Heinrich, Kathrin; Giessen-Jung, Clemens; Neumann, Jens; Kirchner, Thomas; Jung, Andreas; Stintzing, Sebastian; Heinemann, Volker
FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases - The PARLIM trial (AIO KRK 0314)

FOLFOX加帕尼单抗或FOLFOX单独作为RAS野生型结直肠癌肝转移基本传染数/1切除后的附加疗法-PARLIM试验 (AIO KRK 0314)

EUROPEAN JOURNAL OF CANCER
IF7.1
2022-09-014
PRE
Modest, Dominik Paul; Karthaus, Meinolf; Kasper, Stefan; Moosmann, Nicolas; Keitel, Verena; Kiani, Alexander; Uhlig, Jens; Jacobasch, Lutz; Weikersthal, Ludwig Fischer, V; Fuchs, Martin; Kaiser, Florian; Lerchenmueller, Christian; Sent, Dagmar; Junghanss, Christian; Held, Swantje; Lorenzen, Sylvie; Kaczirek, Klaus; Jung, Andreas; Stintzing, Sebastian; Heinemann, Volker

研究方向

暂未获取到该数据
D
Dominik Paul Modest
H 指数:44论文数:436被引数:9,223
S
Sebastian Stintzing
H 指数:49论文数:799被引数:1.1万
L
Ludwig Fischer von Weikersthal
H 指数:41论文数:292被引数:9,563
A
Arndt Stahler
H 指数:16论文数:162被引数:990
V
Volker Heinemann
H 指数:91论文数:1,250被引数:4.3万
T
Thomas Decker
H 指数:61论文数:573被引数:1.6万
K
Kathrin Heinrich
H 指数:20论文数:161被引数:2,692
F
Frank Kullmann
H 指数:47论文数:343被引数:1.2万
F
Florian Kaiser
H 指数:29论文数:293被引数:4,495
A
Andreas Jung
H 指数:70论文数:399被引数:2.1万